John M. Farah Jr.
Senior Clinical Consultant/Clinical Science Liaison, Veradigm
John M. Farah Jr, PhD has over 30 years of experience in health care and the biopharmaceutical industry. Recently, he has been a senior clinical consultant with Veradigm, an Allscripts business, leveraging real-world evidence for insights into challenges and opportunities for biopharmaceutical firms in patient care for chronic conditions. John previously advised clients in drug and biologic development and corporate partnering as Managing Director of his own consultancy and in market access and market research with agencies like rjSynergy. John began advising small to mid-sized firms after 19 years at Cephalon (now Teva) where he rose to Vice President of international pharmaceutical operations. John has broad expertise in R&D, business development, and ex-US commercialization with specialization in Asia Pacific and Latin American markets focusing on products for neurosciences & pain, hematology & oncology, and infectious & inflammatory disorders. John led Cephalon’s headquarter team with P&L responsibilities and oversight of ex-US strategic product registrations, operations, market access and revenue development. He joined Cephalon in 1992 to manage scientific affairs to enhance the company’s R&D initiatives through academic and federal partnerships followed by senior roles in worldwide business development to promote, negotiate and close R&D and commercial deals with multinational and regional pharmaceutical companies. In addition, John co-led successful intellectual property litigation efforts in Europe and Latin America and was Treasurer and director of Cephalon’s political action committee. John has over 10 years of experience as an independent director on the boards of public companies including service on audit, compensation, and governance committees. John is author and inventor on over 40 publications, whitepapers, and patents. He started his industry career as a research investigator in neurosciences and immune-inflammatory programs at G.D. Searle & Co. (now Pfizer) after earning his doctorate in physiology from the Uniformed Services University and conducting post-doctoral studies in the Neurological Disorders and Stroke division of the National Institutes of Health. He has been a guest lecturer in graduate programs at Drexel University, Penn State University, St. Joseph’s University, and St. Louis University.